Innovative Soft Mist Inhaler formulation, based on the excipient technology.


AQ002M, fixed ICS-LABA combination for soft mist inhaler

By reformulating existing ICS and LABA with its proprietary excipient technology, Aquilon Pharma makes ICS-LABA combinations soluble in water. This allows AQ002M to be optimized for any type of Soft Mist Inhaler.


The answer to today’s needs in the field of asthma medication

The recently revised therapy standards advocates the use of a fixed combination of low dose formoterol and ICS as basic treatment of asthma.

ICS-LABA can be delivered via several types of devices, however it is currently not deliverable via Soft Mist Inhaler. Unfortunately, there is no ICS-LABA in liquid formulation available yet for these devices.

Aquilon Pharma’s AQ002M formulation is the key. Aquilon Pharma is currently the ONLY development company capable of formulating an Ultra Low Dose Budesonide-Formoterol for lung delivery through Soft Mist Inhaler, what makes AQoo2M a real Groundbreaker*

*Groundbreaker = Ultra low dose fixed combination Budesonide – Formoterol for PRN use, delivered by Innovative Inhaler based on the Soft Mist Inhaler technology


Aquilon Pharma has strong patents covering the combination of ICS-LABA and its excipient platform up to 2039. Several patents are granted in most of the key countries around the globe.

Medical advantages

Thanks to Aquilon Pharma’s excipient, AQ002M …

  • Shows prolonged airway activity for the same drug concentration
  • Has a better diffusion in the lungs
  • Is more efficient than existing suspensions at a lower dose
  • Improves the efficiency of the administration
  • Is compatible with SoftMist Inhaler (low carbon footprint, hand-held)
  • Minimizes the risk of side effects
  • Minimizes the risk of misuse


Contact us

Do you have a question? Let's get in touch.